Minimal Residual Disease or Cure in MPNs? Rationales and perspectives on Combo Therapy with Interferon-alpha2 and RuxolitinibJune 29, 2017
ASH 2017 Nutlin Antagonist Shows Activity in Polycythemia VeraDecember 27, 2017
One Simple Criteria
If your doc has never been to the ASH (American Society of Hematology) conference, the largest hematology convention in the world and never published a peer reviewed research paper, he/she ain’t likely to be an MPN specialist
. Also, if their bio lists 10 – 12 clinical interests, their focus is NOT likely on MPN’s. 4 to 5 clinical interests would be a reasonable amount to maintain a research study interest in Myeloproliferative Neoplasms. Past or present participation in a clinical trial is also a good indicator.
Dr. Michael Grunwald (my doc) has 7 papers this year. One thing I find interesting….his conclusion on the REVEAL study (which I participate in) is that even if your blood counts are controlled, you may continue to experience PV related symptoms – FATIGUE is still the worst one for me.